Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines reports developments for a central nervous system precision neuroscience biopharmaceutical company focused on therapies for disorders involving neuronal excitation-inhibition imbalance. Its recurring updates cover the Cerebrum small molecule platform, the Solidus antisense oligonucleotide platform, and product candidates across movement disorders and epilepsy, including ulixacaltamide, relutrigine, vormatrigine and elsunersen.
Company news commonly addresses FDA review activity, clinical trial data, scientific presentations, operating and financial results, commercial-readiness updates, equity inducement grants under Nasdaq rules and governance matters. Disease areas highlighted in its disclosures include essential tremor and developmental and epileptic encephalopathies associated with SCN2A and SCN8A.
Praxis Precision Medicines (NASDAQ: PRAX) announced FDA alignment to convert the EMBRAVE3 registrational study of elsunersen in early-onset SCN2A developmental and epileptic encephalopathy to a single-arm, baseline-controlled design.
Key changes: enrollment target reduced to 30 patients from 40, all screening patients will receive elsunersen for 24 weeks then enter an open-label extension, and the primary endpoint is change from baseline in countable motor seizures. Enrollment is accelerating and topline results are expected in 2026; EMBRAVE Part A (n=9) topline readout is expected in 1H 2026.
Praxis (NASDAQ: PRAX) reported clinical updates presented at AES on December 6, 2025, covering relutrigine (EMBOLD) and vormatrigine (RADIANT).
EMBOLD: relutrigine (n=51) produced a 53% placebo‑adjusted seizure reduction over 16 weeks (p<0.0002), a 66% increase in motor seizure‑free days (p=0.034), broad functional improvements, and no drug‑related serious adverse events; Praxis will meet the FDA to discuss an NDA and then decide filing timing.
RADIANT: vormatrigine (FOS n=62) delivered a 54% median seizure reduction at 8 weeks, 58% ≥50% responders in week 1 rising to 61% by week 8, with 100% median weekly seizure reduction by week 8 maintained to 16 weeks; generalized epilepsy cohort (n=3) showed similar effects. POWER1 recruiting complete; POWER2 on track to finish H2 2026; POWER3 monotherapy to start H1 2026.
Praxis Precision Medicines (NASDAQ: PRAX) announced positive topline results from the registrational cohort of the EMBOLD study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs).
A Data Monitoring Committee recommended an early stop for efficacy. Praxis will present topline results at the American Epilepsy Society Annual Meeting on December 6, 2025 and has a confirmed meeting with the FDA to review the data and discuss next steps; the company will decide on NDA timing after that meeting.
Praxis Precision Medicines (NASDAQ: PRAX) completed a pre-NDA meeting with the FDA for ulixacaltamide in essential tremor and received written feedback plus an in-person discussion. The company said it gained alignment with the agency on NDA content and expects to submit the NDA in early 2026. Praxis highlighted momentum from the positive Essential3 program, where ulixacaltamide showed statistically significant, clinically meaningful improvements in daily functioning. Management framed the FDA feedback as advancing the program toward a potential new treatment for millions living with essential tremor.
Praxis Precision Medicines (Nasdaq: PRAX) announced on Dec 1, 2025 that its Compensation Committee granted restricted stock unit awards covering 3,594 shares to six new non-executive employees under the 2024 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The awards were issued as inducements material to the employees joining Praxis and will vest in four equal annual installments, subject to continued employment on each vesting date. The 2024 Inducement Plan is limited to equity awards for individuals not previously employed by Praxis or returning after a bona fide break in service.
Praxis Precision Medicines (NASDAQ: PRAX) will present new preclinical and clinical data across its precision epilepsy portfolio at the American Epilepsy Society Annual Meeting, Dec 5–9, 2025 in Atlanta.
Praxis will host a scientific exhibit and booth #217, and deliver multiple poster and late-breaking presentations including full RADIANT results showing vormatrigine seizure reductions, EMBOLD OLE relutrigine data, PAC-DEE preclinical framework updates, antisense oligonucleotide emergency use cases for SCN2A DEE, and DDI and preclinical findings across programs.
Praxis Precision Medicines (NASDAQ: PRAX) announced an expert fireside chat on November 24, 2025 at 1:00 PM EST to discuss a deep dive into clinical data for ulixacaltamide. The event will be hosted by HC Wainwright analyst Doug Tsao and feature UCSF statistician Prof. Chuck McCullough alongside Praxis CEO Marcio Souza. The session focuses on interpretation of ulixacaltamide clinical results and will include an analyst-led discussion; registration is available via the company’s provided link.
Praxis Precision Medicines (Nasdaq: PRAX) announced on November 6, 2025 that its Compensation Committee granted restricted stock unit awards covering 6,876 shares to six new non-executive employees under the 2024 Inducement Plan.
The awards were granted on November 3, 2025 as inducements under Nasdaq Listing Rule 5635(c)(4) and will vest in four equal annual installments, subject to continued employment on each vesting date. The 2024 Inducement Plan is used exclusively for equity awards to individuals who were not previously employees or who return after a bona fide non-employment period.
Praxis Precision Medicines (NASDAQ: PRAX) will attend and present at multiple investor conferences in November 2025, including corporate presentations and a fireside chat.
Scheduled events:
- Truist Securities BioPharma Symposium — Nov 6, 2025 at 10:40am ET, Lotte New York Palace Hotel, New York City.
- HC Wainwright Emerging Ideas on BioPharma — Nov 7, 2025 at 12:30pm ET, fireside chat with analyst Doug Tsao (registration available).
- Guggenheim Securities Healthcare Innovation Conference — Nov 10, 2025 at 9:30am ET, InterContinental Boston; live webcast available.
- Jefferies Global Healthcare Conference — Nov 18, 2025 at 1:30pm GMT, Waldorf Hilton London; live webcast available.
Replays of the third quarter earnings webinar and conference webcasts will be posted on Praxis’ Events and Presentations page for approximately 90 days after each event.
Praxis Precision Medicines (NASDAQ: PRAX) reported positive Phase 3 results for ulixacaltamide in essential tremor (Essential3), with Study 1 showing a 4.3-point mean mADL11 improvement at Week 8 (p<0.0001) and Study 2 showing 55% vs 33% maintained response (p=0.037). A pre-NDA meeting with FDA is scheduled for Q4 2025. Praxis plans an interim EMBOLD analysis for relutrigine in Q4 2025 that could support an NDA in early 2026. Vormatrigine POWER1 recruitment is complete with topline readout expected 1H 2026. Pro forma cash and investments are ~$956M, expected to fund operations into 2028.